LIFECORE BIOMEDICAL, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$3.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $45.00K.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.65M.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$3.56M.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-05-25 was -$3.50M, a 159.92% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$5.92M, a 458.08% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.65M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 7 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.61M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$3.65M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | -$930.00K 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | -$3.56M 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | -$3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.27M 10-Q · filed 2026-08-05 | -$5.92M 10-KT · filed 2026-03-16 | ||
| 2025-02-23 | $225.00K 10-Q · filed 2026-05-06 | -$2.42M 10-Q · filed 2025-04-03 | |||
| 2024-08-25 | -$273.00K 10-Q · filed 2025-11-06 | $5.56M derived: sum of 2 quarters · filed 2026-03-16 | |||
| 2024-05-26 | $5.84M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $1.65M 10-KT · filed 2026-03-16 | |||
| 2024-02-25 | -$4.18M 10-Q · filed 2025-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |